During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in ...

Semaglutide and other GLP-1 receptor agonists show robust benefit in polycythemia vera, but it’s unclear whether this is due ...

GLP-1a treatment in patients with polycythemia vera was linked to significant reductions in mortality, disease progression, and serious complications.

"Our studies have shown potential benefit of GLP-1 receptor agonists in polycythemia vera," he said. "Obviously, randomized ...

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, ...

Incyte INCY announced new 24-week interim data from the STOP-HS program on pipeline candidate, povorcitinib (INCB54707), in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...

Getting your Trinity Audio player ready... Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development ...